Merck Prices EUR 1.0 Billion Debt Offering
October 26, 2016 12:31 pm ET
Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States
and Canada, priced today a EUR 1.0 billion public offering of two series
of Euro-denominated senior unsecured notes (collectively, the “New
Notes”). Based on Oct. 21, 2016, closing exchange rates the EUR 1.0
billion equates to approximately $1.087 billion. The notes include:
EUR 500 million of 0.500% notes due Nov. 2024
EUR 500 million of
1.375% notes due Nov. 2036
Merck intends to use the net proceeds from the offering for general
corporate purposes, including without limitation repayment of
outstanding commercial paper borrowings and other indebtedness with
upcoming maturities. The offering is expected to close on Nov. 2, 2016,
subject to customary closing conditions. BNP Paribas, Citigroup Global
Markets Limited, and Merrill Lynch International are acting as the
active joint book-running managers for the offering.
The offering of the New Notes is being made pursuant to an effective
shelf registration statement (including a base prospectus) filed with
the Securities and Exchange Commission (SEC). The offering may be made
only by means of a prospectus and related prospectus supplement, copies
of which may be obtained by calling BNP Paribas at (800) 854-5674,
Citigroup Global Markets Limited at (800) 831-9146, or Merrill Lynch
International at (800) 294-1322. An electronic copy of the registration
statement and prospectus supplement, together with the base prospectus,
is available on the SEC’s website at www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein, nor
shall there be any sale of these securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
About Merck
For 125 years, Merck has been a global health care leader working to
help the world be well. Merck is known as MSD outside the United States
and Canada. Through our prescription medicines, vaccines, biologic
therapies and animal health products, we work with customers and operate
in more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Such statements may include, but are not limited to,
the company’s ability to complete the offering and the company’s
expectations for the use of proceeds from the offering. These statements
are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. If
underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth
in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2015 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Merck & Co., Inc.
Media:
Lainie Keller, 908-236-5036
Tracy Ogden, 267-305-2301
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898
